IBRX
Immunitybio Inc
8.60$
-7.1%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3,100.0% | +1,050.0% | +145.0% | +54.3% | +71.7% | +47.0% | -9.3% | +12.3% | +141.6% | -46.4% | -5.2% | -11.6% | |
| – | -10.7% | +26,670.7% | -65.0% | -49.9% | -94.5% | +67.4% | -36.1% | +2,514.6% | -29.7% | +22.4% | -30.0% | +6.9% | |
| – | – | – | – | – | – | -104.5% | – | +357.5% | -50.3% | – | – | – | |
| – | +7,024.8% | -99.5% | +1,262.4% | -16.0% | -117.2% | – | – | -194.1% | – | – | -607.4% | – | |
| – | +9,866.7% | +649.5% | +192.7% | +430.7% | -62.4% | -67.3% | -61.1% | +1,911.0% | +132.9% | -60.9% | -77.5% | -44.2% | |
| – | +9,866.7% | +58,503.3% | -35.1% | – | -42.6% | -67.5% | -206.8% | +328.5% | – | -211.6% | -59.8% | +1,123.3% | |
| – | – | – | – | – | – | – | +95.3% | +7,425.6% | -99.8% | – | – | – | |
| – | – | – | +230.3% | -3.9% | -98.5% | +996.9% | -79.9% | +708.0% | -84.8% | +458.9% | – | – | |
| – | – | – | – | – | – | +33.3% | +33.6% | +431.4% | -48.6% | +48.5% | -100.0% | – | |
| – | +7,016.8% | +392.7% | -104.9% | +124.8% | -97.8% | – | +31.8% | +235.5% | -53.8% | +139.0% | -49.6% | +42.1% | |
| – | +25,008.5% | +98.8% | -243.7% | – | -144.7% | – | – | – | -152.2% | – | -175.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.